- cafead May 26, 2023 at 11:23: AM
via The market for ulcerative colitis (UC) is filled with various treatment options, and the pipeline is relatively strong. The variety of drug classes currently available for the treatment of UC across the eight major markets (8MM: the US, France, Germany, Italy, Spain, the UK, Japan, and Canada) includes 5-amino salicylates (ASAs), steroids, immunomodulators, anti-tumour necrosis factor (anti-TNF) therapies, anti-interleukin therapies, anti-integrin therapies, Janus kinase (JAK) inhibitors, and sphingosine 1-phosphate (S1P) receptor modulators. A notable agent in the late-stage UC pipeline is Pfizer’s etrasimod, a once-daily oral S1P receptor modulator.
article source
article source